Johnson & Johnson said Monday that it is seeking U.S. approval for the first new type of medicine to fight deadly tuberculosis in more than four decades. The experimental drug, called bedaquiline, also would be the first medicine specifically for treating multi-drug-resistant tuberculosis. That's an increasingly common form in which at least two of the four primary TB drugs don't work. Read more